Loading
A phase 1/2 trial of Cemiplimab in ovarian cancer and endometrial cancer, run by Regeneron Pharmaceuticals, now recruiting.
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab is a phase 1/2 interventional study registered as NCT04590326 by Regeneron Pharmaceuticals, with 612 participants planned, started 2020-12-08 and due to reach its primary completion in 2027-03-25. Interventions recorded: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ubamatamab, Regeneron, Cemiplimab, Endometrial cancer.
Shares Ubamatamab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/